People
Deepali Naair joins Biocon Biologics as Global Head of Brand & Corporate Communications
Deepali brings over 30 years of extensive experience in brand building, marketing, and corporate reputation management across India, ASEAN, and Australia.

Deepali Naair has joined Biocon Biologics Limited (BBL) as its Global Head – Brand & Corporate Communications, a move she announced in her LinkedIn post. The appointment, effective immediately, sees Deepali taking a key leadership position within the global biosimilars company. She will now be part of the Executive Leadership Team (ELT), reporting directly to Shreehas Tambe, CEO & Managing Director, Biocon Biologics, and will be based at the company’s Bengaluru headquarters.
In her new capacity, Deepali is tasked with leading the global brand and corporate communications function. Her responsibilities include developing and implementing a comprehensive strategy covering brand positioning, digital footprint, regulatory communications, financial and corporate reporting, media relations, and employer branding.
Deepali brings over 30 years of extensive experience in brand building, marketing, and corporate reputation management across India, ASEAN, and Australia. Before this move, she served as the Group Chief Marketing Officer at CK Birla Group. During her tenure at CK Birla Group, Deepali was instrumental in defining the Group’s corporate identity, successfully launching new brands, and driving significant strategic transformations across its diverse business units.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics, underscored the significance of her appointment: “Branding and communications are critical for shaping stakeholder perception, building trust, and articulating corporate goals. As Biocon Biologics progresses towards becoming a leading global biosimilars company, I am delighted to welcome Deepali and anticipate her leadership in shaping our global brand and communications strategy.”
Deepali’s addition to the team is expected to bolster Biocon Biologics’ global outreach and strengthen its brand as it continues its mission to enhance healthcare access worldwide through high-quality, affordable biosimilars.